| Literature DB >> 33354163 |
Ying Chen1, Liang-Jun Ye2, Yue Wu1, Bing-Zheng Shen1, Fan Zhang1, Qiang Qu3, Jian Qu4.
Abstract
BACKGROUND: Infective endocarditis (IE) is a complex infectious disease with high morbidity and mortality. The inflammation mechanism of IE is a complex network including interactions of inflammatory cytokines and other components of host response. As an important inflammation marker, the prediction ability of neutrophil-to-lymphocyte ratio (NLR) in IE deserves further investigation.Entities:
Mesh:
Year: 2020 PMID: 33354163 PMCID: PMC7735837 DOI: 10.1155/2020/8586418
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Clinical and hematologic data of study population.
| Characteristics | Patients ( | Controls ( |
| |
|---|---|---|---|---|
| Age (years) | 43.25 ± 17.60 | 42.28 ± 15.85 | 0.86 | |
| Sex (man/female) | 463/215 | 1630/890 | 0.08 | |
| Comorbid conditions and predisposing factors | Rheumatic heart disease | 95 (14.01%) | ||
| Congenital heart disease | 85 (12.54%) | |||
| Sepsis | 35 (5.16%) | |||
| Hypertension | 39 (5.75%) | |||
| Brain disease | 9 (1.33%) | |||
| Coronary artery disease | 74 (10.91%) | |||
| Nephropathy | 84 (12.39%) | |||
| Diabetes | 95 (14.01%) | |||
| Pulmonary infection | 12 (1.77%) | |||
| Cardiac insufficiency | 124 (18.29%) | |||
| Pathogens (no. (%)) | Culture positive | 230 (33.92%) | ||
| Culture negative | 448 (66.08%) | |||
| Gram-positive bacteria | 202 (86.70%) | |||
| Gram-negative bacteria | 16 (6.87%) | |||
| Fungus | 15 (6.43%) | |||
| Inflammatory markers | NEU | 7.17 ± 4.13 | 5.43 ± 3.21 | <0.001 |
| LYM | 2.23 ± 1.71 | 1.85 ± 1.48 | 0.67 | |
| NLR | 6.29 ± 9.36 | 1.87 ± 0.34 | <0.001 | |
| PCT ( | 2.34 ± 9.53 | |||
| CRP (mg/L) | 53.13 ± 55.76 |
NLR: neutrophil-lymphocyte ratio; PCT: procalcitonin; CRP: C-reactive protein; NEU: neutrophils; LYM: lymphocytes.
Figure 1The ROC curves of NLR, NEU, and LYM for predicting all IE patients.
The ROC and AUC data of NLR, NEU, and LYM in predicting the occurrence and outcome of IE patients.
| Groups | Markers | AUC | SD |
| 95% CI | Cut-off | Sensitivity | Specificity | 1-specificity | |
|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||||
| Total IE vs. normal | NLR | 0.817 | 0.012 | <0.001 | 0.794 | 0.839 | 2.681 | 0.690 | 0.880 | 0.120 |
| NEU | 0.66 | 0.015 | <0.001 | 0.631 | 0.689 | 6.425 | 0.476 | 0.976 | 0.024 | |
| LYM | 0.27 | 0.012 | <0.001 | 0.247 | 0.293 | 5.107 | 0.019 | 0.988 | 0.012 | |
| Outcome good vs. bad | NLR | 0.647 | 0.027 | <0.001 | 0.594 | 0.701 | 5.557 | 0.390 | 0.853 | 0.147 |
| NEU | 0.625 | 0.028 | <0.001 | 0.570 | 0.681 | 8.095 | 0.525 | 0.721 | 0.279 | |
| LYM | 0.449 | 0.029 | 0.06 | 0.391 | 0.506 | 4.315 | 0.057 | 0.974 | 0.026 | |
NLR: neutrophil-lymphocyte ratio; NEU: neutrophils; LYM: lymphocytes; AUC: the area under the ROC curve; SD: standard deviation; IE: infective endocarditis.
The ROC and AUC data of NLR in predicting IE with different culture results.
| NLR | AUC | SD |
| 95% CI | Cut-off | Sensitivity | Specificity | 1-specificity | |
|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||||
| Culture positive vs. normal | 0.888 | 0.017 | <0.001 | 0.855 | 0.92 | 3.040 | 0.796 | 0.929 | 0.071 |
| Culture negative vs. normal | 0.782 | 0.105 | <0.001 | 0.753 | 0.811 | 2.675 | 0.621 | 0.881 | 0.119 |
| Gram-negative bacteria | 0.822 | 0.077 | <0.001 | 0.672 | 0.973 | 3.035 | 0.750 | 0.929 | 0.071 |
| Gram-positive bacteria | 0.913 | 0.015 | <0.001 | 0.882 | 0.943 | 3.055 | 0.824 | 0.931 | 0.069 |
| Fungus | 0.625 | 0.107 | 0.096 | 0.416 | 0.834 | 3.910 | 0.467 | 0.974 | 0.026 |
ROC: receiver operating characteristic; CI: confidence intervals; SD: standard deviation; AUC: the area under the ROC curve.
Figure 2The ROC curves of NLR for predicting culture-positive IE and culture-negative IE.
Figure 3The ROC curves of NLR for predicting IE with different infectious pathogens. (a) Gram-positive bacteremia, (b) Gram-negative bacteremia, and (c) fungus.
Infection markers in IE patients with different pathogen culture results.
| Infection markers | Negative culture ( | Positive culture ( | Gram-positive bacteria ( | Gram-negative bacteria ( | Fungus ( |
|
|---|---|---|---|---|---|---|
| PCT ( | 2.37 ± 10.40 | 2.30 ± 7.96 | 2.41 ± 8.51 | 1.42 ± 3.18 | 1.86 ± 2.93 | 0.766 |
| CRP (mg/L) | 49.00 ± 55.77 | 60.85 ± 54.91 | 59.28 ± 54.79 | 65.98 ± 65.88 | 78.23 ± 37.41 | 0.288 |
| NLR | 5.76 ± 8.61 | 7.93 ± 10.14 | 7.27 ± 6.78 | 13.44 ± 16.95 | 11.59 ± 25.39 | 0.021 |
Clinical and hematologic data compared between different clinical outcomes of IE patients.
| Parameters | Good outcome ( | Bad outcome ( |
|
|---|---|---|---|
| Age | 42.56 ± 16.81 | 45.89 ± 20.26 | 0.074 |
| Sex (male) | 377 (70.2%) | 86 (60.99%) | 0.036 |
| Comorbid conditions | |||
| Coronary artery disease | 58 (10.81%) | 16 (11.34%) | 0.853 |
| Nephropathy | 62 (11.55%) | 22 (15.6%) | 0.193 |
| Diabetes | 77 (14.34%) | 18 (12.76%) | 0.632 |
| Pulmonary infection | 9 (1.68%) | 3 (2.13%) | 0.721 |
| Cardiac insufficiency | 103 (19.18%) | 21 (14.89) | 0.241 |
| Hypertension | 29 (5.4%) | 10 (7.09%) | 0.443 |
| Brain disease | 7 (1.3%) | 2 (1.42%) | 1 |
| Predisposing factors | |||
| Rheumatic heart disease | 78 (14.53%) | 17 (12.06%) | 0.452 |
| Congenital heart disease | 68 (12.66%) | 17 (12.06%) | 0.847 |
| Prosthetic valve | 105 (19.55%) | 28 (19.86%) | 0.935 |
| Degenerative valve disease | 75 (13.97%) | 14 (9.93%) | 0.206 |
| Implantable cardiac devices | 32 (5.96%) | 10 (7.09%) | 0.619 |
| Pathogens | |||
| Culture positive | 170 (31.66%) | 61 (43.26%) | 0.010 |
| Culture negative | 367 (68.24%) | 80 (56.74%) | — |
| Gram-positive bacteria | 152 (28.31%) | 47 (33.33%) | 0.243 |
| Gram-negative bacteria | 12 (2.23%) | 5 (3.55%) | 0.375 |
| Fungus | 6 (1.12%) | 9 (6.38%) | 0.001 |
| Inflammatory markers | |||
| NEU | 6.84 ± 4.60 | 9.07 ± 5.60 | <0.001 |
| LYM | 2.23 ± 1.68 | 2.22 ± 1.90 | 0.961 |
| NLR | 3.62 ± 2.61 | 5.80 ± 6.02 | <0.001 |
| PCT ( | 1.94 ± 9.67 | 3.15 ± 7.18 | <0.001 |
| CRP (mg/L) | 50.14 ± 50.23 | 64.24 ± 63.02 | <0.001 |
Figure 4The ROC curve of NLR, NEU, and LYM for predicting good and bad outcomes of IE patients.